PDF(Sci-hub)
Abstract：
Clinical interest in the human intestinal microbiota has increased considerably. However, an overview of clinical studies investigating the link between the human intestinal microbiota and systemic cancer therapy is lacking. This systematic review summarizes all clinical studies describing the association between baseline intestinal microbiota and systemic cancer therapy outcome as well as therapy-related changes in intestinal microbiota composition. A systematic literature search was performed and provided 23 articles. There were strong indications for a close association between the intestinal microbiota and outcome of immunotherapy. Furthermore, the development of chemotherapy-induced infectious complications seemed to be associated with the baseline microbiota profile. Both chemotherapy and immunotherapy induced drastic changes in gut microbiota composition with possible consequences for treatment efficacy. Evidence in the field of hormonal therapy was very limited. Large heterogeneity concerning study design, study population, and methods used for analysis limited comparability and generalization of results. For the future, longitudinal studies investigating the predictive ability of baseline intestinal microbiota concerning treatment outcome and complications as well as the potential use of microbiota-modulating strategies in cancer patients are required. More knowledge in this field is likely to be of clinical benefit since modulation of the microbiota might support cancer therapy in the future.
摘要：
对人类肠道微生物群的临床兴趣已大大增加。然而,目前尚缺乏研究人类肠道菌群与系统性癌症治疗之间联系的临床研究综述.本系统综述总结了所有描述基线肠道微生物群与全身癌症治疗结果之间的关联以及肠道微生物群组成的治疗相关变化的临床研究。进行了系统的文献检索，提供了23篇文章。有强烈的迹象表明肠道微生物群与免疫疗法的结果之间存在密切联系。此外，化疗诱导的感染性并发症的发展似乎与基线微生物群有关.化疗和免疫疗法均引起肠道微生物群组成的急剧变化，可能对治疗功效产生影响。激素治疗领域的证据非常有限。研究设计的巨大异质性，研究人群,和用于分析的方法有限的可比性和结果的概括性。为了未来,需要进行纵向研究,调查基线肠道微生物群对于治疗结果和并发症的预测能力,以及微生物群调节策略在癌症患者中的潜在应用.该领域的更多知识可能具有临床益处，因为微生物群的调节可能会支持未来的癌症治疗。
